Literature DB >> 10539539

Informed consent for PSA screening: does it happen?

D G Federman1, S Goyal, A Kamina, P Peduzzi, J Concato.   

Abstract

CONTEXT: Screening for prostate cancer with serum prostate-specific antigen (PSA) is controversial. Ideally, patients should be aware of the potential benefits and risks related to testing.
PURPOSE: To assess whether patients remembered having PSA screening and to determine whether they recalled having a discussion with their primary care provider about the pros and cons of such testing.
METHODS: A questionnaire was sent to patients who had PSA screening ordered by a primary care practitioner during a 2-month period at a university-affiliated Veterans Affairs medical center. Approximately 3 months after the PSA test was done, patients were asked about their baseline health as well as their knowledge of and attitudes toward screening with PSA and treatment for prostate cancer.
RESULTS: The overall response rate was 197 out of 421 (46%) patients. Among 173 eligible respondents without prostate cancer, 53 (31%) were unaware that their physician had ordered a PSA test. Among the 120 patients who were aware of receiving the test, only 56 (47%) recalled having a discussion with their primary care provider about the risks and benefits of screening. Support for the test was more common among patients who recalled having PSA screening than those who did not recall having the test (91% vs. 70%, respectively; P = 0.003).
CONCLUSIONS: Patients who have PSA screening often are unable to recall relevant facts about the test and may have no knowledge of its associated risks and benefits. The role and effectiveness of obtaining verbal informed consent for PSA screening should be re-evaluated.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10539539

Source DB:  PubMed          Journal:  Eff Clin Pract        ISSN: 1099-8128


  21 in total

1.  Moving towards shared decision making in prostate cancer screening.

Authors:  Richard M Hoffman; Deborah L Helitzer
Journal:  J Gen Intern Med       Date:  2007-07       Impact factor: 5.128

2.  PSA--"prostate-specific antigen" or "patient stress & anxiety": a questionnaire study.

Authors:  Junaid Masood; Azhar Khan; Taufiq Sheikh; Noor Buchholz; Ron Miller; Andrew J Ball
Journal:  Int Urol Nephrol       Date:  2007-04-06       Impact factor: 2.370

3.  Applicability of a video intervention to increase informed decision making for prostate-specific antigen testing.

Authors:  Levi Ross; Alicestine D Ashford; Sherese J Bleechington; Tyra Dark; Deborah O Erwin
Journal:  J Natl Med Assoc       Date:  2010-03       Impact factor: 1.798

4.  Variation in prostate-specific antigen screening in men aged 80 and older in fee-for-service Medicare.

Authors:  Julie Bynum; Yunjie Song; Elliott Fisher
Journal:  J Am Geriatr Soc       Date:  2010-03-22       Impact factor: 5.562

5.  Informed decision making about prostate cancer testing in predominantly immigrant black men: a randomized controlled trial.

Authors:  Stephen J Lepore; Randi L Wolf; Charles E Basch; Melissa Godfrey; Emma McGinty; Celia Shmukler; Ralph Ullman; Nigel Thomas; Sally Weinrich
Journal:  Ann Behav Med       Date:  2012-12

6.  Reconciling primary care and specialist perspectives on prostate cancer screening.

Authors:  Richard M Hoffman; Michael J Barry; Richard G Roberts; Harold C Sox
Journal:  Ann Fam Med       Date:  2012 Nov-Dec       Impact factor: 5.166

7.  National evidence on the use of shared decision making in prostate-specific antigen screening.

Authors:  Paul K J Han; Sarah Kobrin; Nancy Breen; Djenaba A Joseph; Jun Li; Dominick L Frosch; Carrie N Klabunde
Journal:  Ann Fam Med       Date:  2013 Jul-Aug       Impact factor: 5.166

8.  Do Men Receive Information Required for Shared Decision Making About PSA Testing? Results from a National Survey.

Authors:  Bryan Leyva; Alexander Persoskie; Allison Ottenbacher; Jada G Hamilton; Jennifer D Allen; Sarah C Kobrin; Stephen H Taplin
Journal:  J Cancer Educ       Date:  2016-12       Impact factor: 2.037

9.  Best ethical practices for clinicians and laboratories in the provision of noninvasive prenatal testing.

Authors:  M A Allyse; L C Sayres; M Havard; J S King; H T Greely; L Hudgins; J Taylor; M E Norton; M K Cho; D Magnus; K E Ormond
Journal:  Prenat Diagn       Date:  2013-05-21       Impact factor: 3.050

10.  Informed consent for cancer screening with prostate-specific antigen: how well are men getting the message?

Authors:  Evelyn C Y Chan; Sally W Vernon; Frederick T O'Donnell; Chul Ahn; Anthony Greisinger; Donnie W Aga
Journal:  Am J Public Health       Date:  2003-05       Impact factor: 9.308

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.